Richard W. Paul & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Richard W. Paul & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4	Closed	-$3.09K	–	333
2026 Q1	$3.09K	Hold	4	–	–	﹤0.01%	253
2025 Q4	$3.09K	Hold	4	–	–	﹤0.01%	250
2025 Q3	$2.25K	Hold	4	–	–	﹤0.01%	275
2025 Q2	$2.1K	Hold	4	–	–	﹤0.01%	299
2025 Q1	$2.54K	Hold	4	–	–	﹤0.01%	277
2024 Q4	$2.85K	Hold	4	–	–	﹤0.01%	395
2024 Q3	$4.21K	Hold	4	–	–	﹤0.01%	356
2024 Q2	$4.2K	Hold	4	–	–	﹤0.01%	353
2024 Q1	$3.85K	Hold	4	–	–	﹤0.01%	375
2023 Q4	$3.51K	Hold	4	–	–	﹤0.01%	373
2023 Q3	$3.29K	Sell	4 -3	-43%	-$2.36K	﹤0.01%	368
2023 Q2	$5.03K	Hold	7	–	–	﹤0.01%	363
2023 Q1	$5.75K	Hold	7	–	–	﹤0.01%	365
2022 Q4	$5.05K	Buy	+7	New	+$5.17K	﹤0.01%	369

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Richard W. Paul & Associates's REGN Position: Q2 2026 in Review

Richard W. Paul & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 4 shares — an estimated $3.09K sold.

Richard W. Paul & Associates first reported a position in REGN in Q4 2022 and held it in 14 quarters. The position peaked at $5.75K in Q1 2023. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Richard W. Paul & Associates reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Richard W. Paul & Associates sold 4 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.09K.
Richard W. Paul & Associates first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 14 quarters.
Richard W. Paul & Associates's Regeneron Pharmaceuticals position peaked at $5.75K in Q1 2023.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Richard W. Paul & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.